GEN Exclusives

More »

The Lists

More »
Jul 22, 2013

Top 25 Biotech Companies of 2013

Which firms made this list this time?

Top 25 Biotech Companies of 2013

These 25 biotech firms are ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares.

  • #13. UCB

    2013 Market Cap: $11.650 billion (3/31: 179.3 million shares * price €49.80 on 3/29)1,6

    2012 Market Cap: $7.449 billion (3/31: 176.4 million shares * price €32.35 on 3/30)1,6

    % Change: 56.4%

    Position on 2012 List: #14

  • #12. Vertex Pharmaceuticals

    2013 Market Cap: $17.495 billion (4/26: 221,400,864 shares * price $79.02)

    2012 Market Cap: $8.151 billion (4/27: 211,061,148 shares * price $38.62)

    % Change: 114.6%

    Position on 2012 List: #11

  • #11. Shire

    2013 Market Cap: $17.252 billion (4/29: 562,826,237 shares * price £20.17)

    2012 Market Cap: $17.205 billion (4/27: 562,532,330 shares * price £20.13 on 4/26)

    % Change: 0.3%

    Position on 2012 List: Not on list

  • #10. Alexion

    2013 Market Cap: $17.893 billion (4/23: 195,146,634 shares * price $91.69)

    2012 Market Cap: $17.152 billion (4/20: 186,924,017 shares * price $91.76)

    % Change: 4.3%

    Position on 2012 List: #10

  • #9. Regeneron

    2013 Market Cap: $20.269 billion (4/17: 95,122,401 shares * price $213.08)7

    2012 Market Cap: $11.894 billion (4/11: 97,966,145 shares * price $121.41)7

    % Change: 70.4%

    Position on 2012 List: #12

  • #8. CSL

    2013 Market Cap: $27.440 billion (6/30: A$30.042 billion) (dd)1,8

    2012 Market Cap: $18.359 billion (6/30: A$20.099 billion) (dd)1,8

    % Change: 49.5%

    Position on 2012 List: #9

  • #7. Merck KGaA

    2013 Market Cap: $33.364 billion (3/31: 217,388,939 shares * price €117.70 on 3/29)4

    2012 Market Cap: $22.319 billion (3/31: 217,388,939 shares * price €78.72 on 3/30)4

    % Change: 49.5%

    Position on 2012 List: #8

  • #6. Teva Pharmaceutical Industries

    2013 Market Cap: $33.768 billion (3/31: About 851 million shares * price $39.68 on 3/28)4,9

    2012 Market Cap: $39.292 billion (3/31: About 872 million shares * price $45.06 on 3/30)4,9

    % Change: -14.1%

    Position on 2012 List: #5

  • #5. Biogen Idec

    2013 Market Cap: $47.157 billion (4/18: 237,374,815 shares * price $198.66)

    2012 Market Cap: $31.582 billion (5/1: 239,562,899 shares * price $131.83)

    % Change: 49.3%

    Position on 2012 List: #4

  • #4. Celgene

    2013 Market Cap: $52.557 billion (4/23: 417,122,477 shares * price $126.00)

    2012 Market Cap: $34.319 billion (4/25: 440,497,817 shares * price $77.91)

    % Change: 53.1%

    Position on 2012 List: #7

  • #3. Gilead Sciences

    2013 Market Cap: $78.373 billion (4/26: 1,525,355,825 shares * price $51.38)

    2012 Market Cap: $19.751 billion (4/27: 757,321,824 shares * price $26.08)

    % Change: 296.8%

    Position on 2012 List: #3

  • #2. Amgen

    2013 Market Cap: $78.695 billion (4/24: 749,976,556 shares * price $104.93)

    2012 Market Cap: $55.054 billion (4/26: 777,707,877 shares * price $70.79)

    % Change: 42.9%

    Position on 2012 List: #2

  • #1. Novo Nordisk

    2013 Market Cap: $85.335 billion (7/2: 535.0 million shares * price DKK 911.50)1,10

    2012 Market Cap: $62.809 billion (7/2: 418.0 million shares * price DKK 859.00)1,10

    % Change: 35.9%

    Position on 2012 List: #1


Readers' Comments

Posted 07/28/2013 by James Thornton

It would be helpful if you also were to list the main product line or service provided by these companies.
Jim Thornton

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?